Bruno Achutti Duso

@DusoBruno

Brazilian born/Italian grounded physician, early drug development fellow , molecular oncology PhD student, science hunger.

Milan, MI
Vrijeme pridruživanja: kolovoz 2017.

Tweetovi

Blokirali ste korisnika/cu @DusoBruno

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DusoBruno

  1. proslijedio/la je Tweet
    15. srp 2019.
    Poništi
  2. proslijedio/la je Tweet
    23. svi 2019.

    sj Miller () lends insight into our perception of gender and the distress that people with nonconforming gender identities often feel trying to fit into a binary world. 2018

    Poništi
  3. 8. ožu 2019.

    Omloop Het Nieuwsblad: Woman cyclist stopped after catching men - CNN

    Poništi
  4. proslijedio/la je Tweet
    24. velj 2019.

    ESMO's Research Fellowships - Excellent opportunities for young oncologists to develop high-quality projects in either translational or clinical research. More details here

    Poništi
  5. 26. velj 2019.

    Bare, simple educational scheme by Aurélien Marabelle on why we avoid using medians when accessing outcomes in IO.

    Poništi
  6. proslijedio/la je Tweet

    Interesting talks this morning at , highlighting the biological rationale for combining CDK4/6i with PD-(L)1 blockade, as well as the potential detrimental effect of combining co-stimulatory receptor (OX40) agonists with PD-1 inhibitors.

    Poništi
  7. 26. velj 2019.

    This is such a clear view on how different cell niches may respond to different therapies (no wonder PR is our most common outcome on clinical trials). Thumbs up, Benjamin Izar.

    Poništi
  8. 25. velj 2019.

    Ok, the concept of turning immunotherapy ‘cold’ tumors into ‘hot’ by chemo-induced mutations has seen better days, but when it comes to pushing MMRd at our favor for therapeutic purposes, what are your thoughts about it?

    Poništi
  9. 25. velj 2019.

    Subtracting single cell copy number alteration baseline profile from after therapy analysis may give valuable info on specific acquired resistance mechanisms - a root cause method applied by Prof Johann De Bono at

    Poništi
  10. proslijedio/la je Tweet

    The University of Global Health Equity, a initiative, is the world’s first medical school dedicated to global health equity

    Poništi
  11. proslijedio/la je Tweet

    Impassion can be a positive emotion but careless expression of it is inappropriate. With increasing interest in atezolizumab in breast cancer particularly after the oral presentation, here are my few thoughts....1/n @VPplenarysesh

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    18. ruj 2018.

    Liquid biopsies for cancer have gained a new dimension. Beyond CTC, ctDNA or mRNA, now a functional assay that quantifies proteases secretion from CTC has been implemented. These outlier protease-secreting CTC may drive metastasis & immune evasion.

    Poništi
  13. proslijedio/la je Tweet
    6. ruj 2018.

    Our perspective on CIN and the tumor microenvironment out today in : the two sides of in . It’s all context dependent - new ways to target CIN as a therapeutic vulnerability

    Poništi
  14. proslijedio/la je Tweet

    Selective kinase inhibition for patients with RET-altered cancers

    Poništi
  15. proslijedio/la je Tweet
    25. kol 2018.

    Looking forward to the full release of the SOLAR-1 data. This trial testing the alpha-specific PI3K inhibitor BYL719+fulvestrant vs. fulvestrant in HR+/HER2-/PIK3CAmt met its PFS endpoint. PIK3CAmt has been found in 35.7% of our breast ca pts.

    Poništi
  16. proslijedio/la je Tweet
    7. ruj 2018.

    Exosomes are an underappreciated vector of body communication. Their impact in cancer was recently highlighted in melanoma when PDL1 + exosomes were identified as a source of resistance to Great review: a must read !

    Poništi
  17. proslijedio/la je Tweet
    5. ruj 2018.

    Ethnicity contributed to explain interindividual dissimilarities in gut microbiota composition...

    Poništi
  18. proslijedio/la je Tweet
    17. kol 2018.

    More evidence that in the US, cancer outcomes are due to access and socioeconomic status which are largely normalized in cooperative group trials. Studies that do not consider wealth and geography in population outcomes are meaningless.

    Poništi
  19. proslijedio/la je Tweet
    9. kol 2018.

    BET inhibition + aPD-1 in KRAS mutant Nice work from KK Wong in his new gig. FWIW I don't think it's going to be that easy in patients, but it's a neat conceptual framework for trials. In Cancer Immunol Res

    Poništi
  20. proslijedio/la je Tweet
    5. kol 2018.

    If only he had lived to transform US medical education and practice...

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·